Sirolimus in metatastic renal cell carcinoma

被引：12

作者：

Brugarolas, James ^{[1
,2
]}

Lotan, Yair

Watumull, Lori ^{[3
]}

Kabbani, Wareef ^{[4
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Oncol, Dallas, TX 75390 USA

[2] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Dev Biol, Dallas, TX 75390 USA

[3] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA

[4] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 20期

关键词：

D O I：

10.1200/JCO.2008.16.4590

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3457 / 3460

页数：5

共 12 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2] Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer [J].

Boni, JP ;

Leister, C ;

Bender, G ;

Fitzpatrick, V ;

Twine, N ;

Stover, J ;

Dorner, A ;

Immermann, F ;

Burczynski, ME .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :76-89

[3] Renal-cell carcinoma - Molecular pathways and therapies [J].

Brugarolas, James .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :185-187

[4] TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].

Brugarolas, JB ;

Vazquez, F ;

Reddy, A ;

Sellers, WR ;

Kaelin, WG .

CANCER CELL, 2003, 4 (02) :147-158

[5] Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib [J].

Chu, Tammy F. ;

Rupnick, Maria A. ;

Kerkela, Risto ;

Dallabrida, Susan M. ;

Zurakowski, David ;

Nguyen, Lisa ;

Woulfe, Kathleen ;

Pravda, Elke ;

Cassiola, Flavia ;

Desai, Jayesh ;

George, Suzanne ;

Morgan, Jeffrey A. ;

Harris, David M. ;

Ismail, Nesreen S. ;

Chen, Jey-Hsin ;

Schoen, Frederick J. ;

Van den Abbeele, Annick D. ;

Demetri, George D. ;

Force, Thomas ;

Chen, Ming Hui .

LANCET, 2007, 370 (9604) :2011-2019

[6]

DUTCHER JP, 2007, J CLIN ONCOL, V26, pS18

[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[8] Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system [J].

Lam, JS ;

Shvarts, O ;

Leppert, JT ;

Pantuck, AJ ;

Figlin, RA ;

Belldegrun, AS .

JOURNAL OF UROLOGY, 2005, 174 (02) :466-472

[9] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[10] Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer [J].

Raymond, E ;

Alexandre, J ;

Faivre, S ;

Vera, K ;

Materman, E ;

Boni, J ;

Leister, C ;

Korth-Bradley, J ;

Hanauske, A ;

Armand, JP .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2336-2347

← 1 2 →